US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Rhenman & Partners strengthens its investor relations team

Rhenman & Partners hires Tom Josephson as Investor Relations Director. Tom, together with Erica von Bahr (also part of the Investor Relations team), will work with investors in Sweden and internationally. Tom's main focus will however be on Nordic investors. Tom joins Rhenman & Partners from Brummer & Partners, where he spent nearly 18 years responsible for institutional investors in the Nordic region. During his career, he has also worked at Nordea Investment Management, Goldman Sachs, Brown Brothers Harriman and SEB.   “I am excited to join Rhenman & Partners. With their active

Rhenman & Partners strengthens its investment team with a biopharma analyst

Press release December 2022Rhenman & Partners hires Amennai Beyeen as biopharma analyst. Amennai will have a particular focus on biopharma companies and the development of new drugs and treatments. He will be working closely with all colleagues of Rhenman & Partners' five-person investment team, all based in the firm’s Stockholm office. Most recently Amennai comes from Novartis, where he works with development and launches of new drugs. Amennai has previously obtained a doctorate in neuroimmunology at Karolinska Institutet in Stockholm, Sweden."We are very happy to welcome Amennai to

Teresa Isele to be the new CEO of Rhenman & Partners Asset Management AB

Press release Stockholm, 30 September 2022   Rhenman & Partners Asset Management AB appoints Teresa Isele as new CEO. Co-founder and current CEO Göran Nordström retires at the age of 69.   Most recently Teresa comes from the role as CEO at Swedsec, which provides a licensing system for employees within the Swedish financial services industry. Teresa has previously held roles as acting CEO, general counsel and head of compliance at AP1 (Första AP-fonden) and as a lawyer at EQT and at the law firm Vinge. Teresa will assume the role as CEO at Rhenman & Partners in March 2023.

Rhenman Healthcare Equity L/S winner at the HFM European Performance Awards 2021: Global equity long-term performance (5 years)

The hedge fund industry gathered to celebrate the best performing funds in 45 different categories at the HFM European Performance Awards 2021. The judging panel members, specifically chosen because of their expertise within alternative investments, voted Rhenman Healthcare Equity L/S as the winner in the Global equity long-term performance (5 years) category. The panel, consisting of institutional and private investors as well as investment consultants, carefully reviewed the nominees in each category following a method used by institutional investors to select the winners. “We are

Rhenman & Partners wins international fund award at Hedgeweek European Awards: Best Global Hedge Fund

European institutional investors, high net-worth individuals, investment advisors, fund managers, and prime brokers have chosen Rhenman Healthcare Equity L/S as the winnerin the category “Best Global Equity Hedge Fund” of Hedgeweek Awards 2021. Voting took place following a nomination procedure where the specialist newswire Hedgeweek, in cooperation with Bloomberg, selected the best performing European hedge funds. A total of 21,715 industry experts participated in the final voting. “We are extremely pleased with this award which, of course, reflects the strong performance of the fund,

Rhenman & Partners wins prestigious award at the Nordic Hedge Awards: Best Performance Awards for 5 Years

Since inception in June 2009, the fund has had annualised returns of +19%The sector fund Rhenman Healthcare Equity L/S was named a winner at this year’s Nordic Hedge Awards; best-performing Nordic hedge fund for five years. The award was made in the category "Performance Award for 60 Months". "We are tremendously pleased over this award. The Nordic Hedge Award is the most prestigious Nordic award for hedge funds and a total of 172 funds were evaluated in 2018. To put it simply, this is the Nordic championship and to win the category for the longest time period is a testament to our

Rhenman & Partners wins four prestigious awards at the Nordic Hedge Awards

The sector fund Rhenman Healthcare Equity L/S was named as a four-time winner at this year’s Nordic Hedge Awards; best hedge fund of all Nordic hedge funds (of which there are 154), best Nordic equity hedge fund, and best-performing Nordic hedge fund for one and five years respectively.  The awards were made in the categories "Best Nordic Hedge Fund Overall 2017", “Best Nordic Equity Hedge Fund 2017", "Performance Award for 12 Months" and "Performance Award for 60 Months".   "We are tremendously pleased over these awards. The Nordic Hedge Award is the most prestigious Nordic award

Rhenman & Partners continues its strategic expansion

Susanna Urdmark recruited as Portfolio Manager Rhenman & Partners Asset Management is continuing to expand and has now tied another key person to its Healthcare Team. Susanna Urdmark becomes a new Portfolio Manager for the Healthcare fund Rhenman Healthcare Equity L/S, together with Henrik Rhenman.Susanna Urdmark has extensive experience from both the stock market and the life science sector. Most recently, she was at the Stockholm-based pharmaceutical company Bluefish Pharmaceuticals, where she has been a CFO and a senior management member since 2007. Prior to that, she worked as

New fund Rhenman Global Opportunities L/S to be launched on August 31

An active long / short equity mandate with the goal of generating 7-8% annual net return Rhenman & Partners Asset Management will on August 31, 2016, start a new global equity L/S fund - Rhenman Global Opportunities L / S - which can invest in all sectors worldwide. Fund manager is Staffan Knafve, with almost 30 years experience as an analyst and manager.Rhenman Global Opportunities L/S will make its investments based on active selection of regions and sectors, completely independent of index. The fund will take 35-50 positions, preferably in larger companies. The investment horizon for

Rhenman & Partners starts new fund: Rhenman Global Opportunities L/S

An active long / short equity mandate with the goal of generating 7-8% annual net returnRhenman & Partners Asset Management will on May 31, 2016 start a new global equity L/S fund - Rhenman Global Opportunities L / S - which can invest in all sectors worldwide. Fund manager is Staffan Knafve, with almost 30 years experience as an analyst and manager.Rhenman Global Opportunities L/S will make its investments based on active selection of regions and sectors, completely independent of index. The fund will take 35-50 positions, preferably in larger companies. The investment horizon for long

Rhenman & Partners wins prestigious awards at the Nordic Hedge Awards: best overall 3-year and 5-year performance

The sector fund Rhenman Healthcare Equity L / S was awarded for the best overall performance among all the Nordic hedge funds at the Nordic Hedge Awards. The awards relate to overall performance over a period of three and five years.The winning categories were ”Best Net Performance - 3 Years” as well as ”Best Net Performance - 5 Years”. “We are extremely pleased to receive these awards. This is the most respected prize in the Nordic region for hedge funds, which clearly demonstrates our ability to generate substantial long-term value for our investors. To be the best hedge fund over

Rhenman Healthcare Equity L/S awarded international prize for Long Term Performance – Equity Strategies (5 Years) at EuroHedge Awards in London

The first Nordic fund to receive this awardThe fund returned +245% during the five-year period (+28% annualised)Since inception in June 2009, the fund has returned a total of +323% The sector fund Rhenman Healthcare Equity L/S was awarded Long Term Performance – Equity Strategies (5 Years) at the prestigious EuroHedge Awards in London. The prize refers to the period 2011-2015 and was awarded by Goldman Sachs. "We are extremely pleased to receive this award. This is the most respected international prize in Europe for hedge funds, which demonstrates our ability to generate

Rhenman Healthcare Equity L/S awarded two prizes at Nordic Hedge Awards

Best Nordic Equity Focused Hedge Fund 2014 and Best Performing Nordic Hedge Fund 2014Since inception in June 2009, the Fund has returned a total of +349%, which translates to 30% annualised The Rhenman Healthcare Equity L/S, which invests in listed companies primarily in pharmaceuticals, medical technology, biotechnology and services, was awarded Best Nordic Equity Focused Hedge Fund 2014 and Best Performing Nordic Hedge Fund 2014 at the Annual Nordic Hedge Awards 2014, which is held to commend fund excellence in the Nordic hedge fund industry. ”This is the most prestigious award in

Rhenman Healthcare Equity L/S awarded EuroHedge’s Best Global Equity Fund with Assets Below $500m

Since inception in June 2009, the Fund has had annualised returns of +26%The Rhenman Healthcare Equity L/S, which invests in listed companies primarily in pharmaceuticals, medical technology, biotechnology and services, was awarded Best Global Equity Fund with assets below $500m at the Annual Eurohedge Awards 2014 held to celebrate fund excellence in the European hedge fund industry.   ”We are very pleased to have been awarded the Best Global Equity Fund under $500m. The team works incredibly hard and it is always enjoyable to have that recognised. The healthcare sector makes up more

Rhenman Healthcare Equity L/S awarded Best Nordic Equity Focused Hedge Fund at the Nordic Hedge Award in Stockholm

Since inception in June 2009, the Fund has increased in value with +92% The sector fund Rhenman Healthcare Equity L/S, which invests in listed companies primarily in pharmaceuticals, medical technology, biotechnology and healthcare, was awarded Best Nordic Equity Focused Hedge Fund at the Nordic Hedge Award, arranged by Nordic Business Media AB, the leading Nordic hedge fund-focused publishing house.”We are very pleased that our fund was awarded best Nordic equity focused hedge fund. The healthcare sector makes up more than 10 per cent of total global market capitalization, so the fund

Rhenman Healthcare Equity L/S ranked as the best fund in EuroHedge

Since its inception in June, 2009, the Fund has increased in value by over 78%. The sector fund Rhenman Healthcare Equity L/S, which invests in listed companies primarily in pharmaceuticals, medical technology, biotechnology and healthcare, has been ranked number 1 based on average annual return among 44 global funds (with more than three years track record) in the latest issue of EuroHedge, which is one of the leading publications for hedge funds in Europe.The ranking is based on the funds' performance, and for Rhenman Healthcare Equity L/S, the annualized compound return is +16.64%

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media